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Abstract  
Aims: A systematic review and meta-analysis were undertaken to estimate the effects of needle 
syringe programmes (NSP) and opioid substitution therapy (OST), alone or in combination, for 
preventing acquisition of Hepatitis C virus (HCV) in people who inject drugs (PWID).  
Methods: Bibliographic databases were searched for studies measuring concurrent exposure to 
current OST (within last 6 months) and/or NSP and HCV incidence among PWID. High NSP coverage 
was defined as regular NSP attendance or ≥100% coverage (receiving sufficient or greater number of 
needles/syringes per reported injecting frequency). Studies were assessed using the Cochrane risk of 
bias in non-randomised studies tool. Random effects models were used in meta-analysis.  
Results: We identified 28 studies (n=6279) in North America (13), UK (5), Europe (4), Australia (5), 
and China (1). Studies were at moderate (2), serious (17) critical (7) and non-assessable risk of bias 
(2). Current OST is associated with 50% (risk ratio (RR) 0.50 95% CI 0.40-0.63) reduction in HCV 
acquisition risk, consistent across region and with low heterogeneity (I2=0, p=0.889). Weaker 
evidence was found for high NSP coverage (RR=0.79 95% CI 0.39-1.61) with high heterogeneity 
(I2=77%, p=0.002). After stratifying by region, high NSP coverage in Europe was associated with a 
56% reduction in HCV acquisition risk (RR=0.44, 95% CI 0.24-0.80) with low heterogeneity (I2=12.3%, 
p=0.337) but not in North America (RR=1.58, I2=89.5%, p=<0.001). Combined OST/NSP is associated 
with a 76% reduction in HCV acquisition risk (RR=0.24 95% CI=0.07-0.89, I2=80% p=0.007). According 
to GRADE criteria, the evidence on OST and combined OST/ NSP is low quality while NSP is very low. 
Conclusions: Opioid substitution therapy reduces risk of hepatitis C acquisition and is strengthened 
in combination with needle syringe programmes There was weaker evidence for the impact of 
needle syringe programmes alone, although stronger evidence that high coverage is associated with 
reduced risk in Europe. 
 
 
Key words:  Opioid substitution therapy, needle/syringe programmes, hepatitis C, incidence, 
substance use, Cochrane, meta-analysis, review, harm reduction  
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Needle syringe programmes and opioid substitution therapy for preventing HCV transmission 
among people who inject drugs: findings from a Cochrane Review and meta-analysis 
 
Introduction  
Hepatitis C virus (HCV) is a major global public health concern, with approximately 114.9 (91.9-
148.7) million people having antibodies to HCV 1, 3-4 million people newly infected each year and 
350,000 deaths occurring annually.2, 3 People who inject drugs (PWID) are the key at risk group in 
most high income countries and in most countries over half of PWID have been infected with HCV.4 
Evidence shows that injecting with needle/syringes previously used by someone else is the main risk 
factor for infection with HIV and HCV among PWID.5, 6 Additional risks for HCV acquisition in this 
population include sharing drug preparation containers, filters, rinse water and backloading (a 
method of sharing drugs by transferring them from the needle of one syringe into the barrel of 
another). {Pouget, 2012 #26}{Strathdee, 2010 #25} The provision of sterile injecting equipment 
through needle and syringe programmes (NSP) and enrolment in opioid substitution treatment (OST) 
are among the primary interventions for reducing HCV and HIV transmission among PWID. NSPs 
provide sterile needles/syringes and other injecting equipment to PWID, via fixed-sites, outreach, 
peer networks, vending machines, and pharmacies. By maximising the amount of sterile injecting 
equipment (including syringes, cookers, cottons) in circulation, the time infected equipment remains 
in circulation decreases and the proportion of unsafe injections or the need to share equipment to 
prepare drugs reduces.7 OST is prescribed to dependent opioid users to diminish the use and effects 
of illicitly acquired opioids and reduce the frequency of injection and exposure to unsafe injecting 
practices.8 The most commonly prescribed forms of OST are opiate agonist treatments - methadone 
maintenance therapy and buprenorphine maintenance treatment. NSPs and OST are often the first 
point of service contact for PWID and so they provide referrals and support to other social and 
welfare services.  
There is good evidence that NSP and OST in combination reduce injecting risk behaviours and some 
evidence of an impact on HIV incidence. However, evidence for their impact on HCV incidence 
among PWID is limited.9-15 Recent reviews have estimated a moderate effect of NSPs in reducing HIV 
transmission by 48% (95% confidence interval (CI) 3-72%) and strong evidence for OST reducing HIV 
transmission by 54% (95% CI 33-68%).{Aspinall, 2014 #38;MacArthur, 2012 #39} Previous evidence 
syntheses for use of NSPs has focussed primarily on HIV as the main outcome and, as a 
consequence, failed to include all the available evidence on HCV. 11 8, 13, 18 Another review that 
measured the effect of NSP use did not include a meta-analysis due to heterogeneity in the 
measurement of NSP exposure and focussed on evidence from North America, limiting the 
generalisability of findings to other settings including Europe.19 An analysis of pooled data examined 
the effect of NSP coverage on HCV incidence showed that high coverage of NSP (≥100% of injections 
with a sterile syringe) or receipt of OST either currently or within the past 6 months can each reduce 
HCV infection risk by 50%; and in combination by 80%. The small number of incident HCV cases 
meant that the efficacy estimate for 100% NSP among those not on OST was weak.20  
 
Evidence of the effect of NSP with and without OST on HCV incidence is inconclusive.{Palmateer, 
2010 #37} There is a need to strengthen this existing evidence base, including a more refined 
measure of coverage of NSP that accounts for frequency and the degree to which the NSP meets 
individuals requirement for needles/syringes in order to inform interventions to reduce the burden 
of HCV. We undertook a Cochrane systematic review and meta-analysis of unpublished and 
published studies. Our primary objective was to assess the impact of NSPs with and without OST on 
the incidence of HCV infection among PWID. Our secondary objective involved estimating any 
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differential effect of variables including duration of treatment, geographical setting, study setting 
(i.e. community, or treatment), sample characteristics (such as age, sex, experience of prison, 
homelessness, use of stimulant injection). Full methods are reported in the Cochrane review.21 
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Methods 
 
Search  
We carried out two separate systematic search strategies. The first identified studies that directly 
examined the impact of OST or NSP in relation to HCV incidence. The second focussed on identifying 
cohort studies that reported HCV incidence among PWID. These studies were examined to identify 
whether they reported the impact of OST or NSP in relation to HCV transmission in secondary 
analyses. Where no measure was reported, authors of studies were contacted and asked if OST or 
NSP exposures were measured and if so to provide unpublished data. The full search terms are 
reported in the Cochrane Review.21 Multiple databases were included up to March 2017 (Medline, 
PsycInfo, Embase, Cochrane Drug and Alcohol Group Specialised Register, the Cochrane Database of 
Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness, Global Health, Cinahl 
(EBSCO Host), Web of Science); as well as conference abstracts of the International HIV/AIDS society 
and the European Association for the Study of Liver conference and the International Symposium on 
Hepatitis Care in Substance Users. Grey literature was searched from European Monitoring Centre 
on Drugs and Drug Addiction and the European Centre for Disease Control. 
Study selection  
Two reviewers screened full text copies of relevant articles to determine whether they met eligibility 
criteria. There was no language restriction.  
Data extraction and analysis 
See the full Cochrane Review21 for the full data extraction form which included study design and 
recruitment; sample characteristics; intervention; outcome measure and intervention effect. Data 
were double extracted. 
Eligibility criteria 
We included all observational (prospective and retrospective cohorts, cross-sectional surveys and 
case-control studies) or experimental studies that: a) measured exposure to either intervention 
against no intervention or a reduced exposure and reported HCV incidence as an outcome; and b) 
reported a minimum of 2 sero-conversions. We included studies that measured incidence of HCV in 
PWID via repeated testing such as detection of HCV RNA positive among HCV negative participants. 
OST exposure was measured through self-report defined as use of prescribed methadone or 
buprenorphine within the last 6 months. High NSP coverage was defined as obtaining 100% of 
needles/syringes from a safe source, reporting obtaining ≥100% of sterile needles/syringes per 
injecting frequency, regular attendance at least once per week at an NSP, or obtaining most 
needles/syringes from an NSP in the last 6 months. We excluded studies measuring HCV incidence 
using self-reported data and those conducted in prison settings.  
 
Risk of bias 
We assessed the quality of included studies through the Cochrane risk of bias assessment tool for 
non-randomized studies of interventions.22 This assesses studies according to seven domains:  
confounding; selection bias; measurement of interventions; departures from intervention; missing 
data; measurement of outcomes; and selection of reported results, to give an overall risk of bias 
classified into four categories of Low to Critical. We decided that minimum adjustment for 
confounding should include time since first injection or age and injecting frequency at baseline. We 
assessed the overall quality of the evidence for the primary outcome using the GRADE system.23 We 
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used funnel plots (plots of the effect estimate from each study against the sample size or effect 
standard error) to assess the potential for bias related to the size of the studies, which could indicate 
possible publication bias.  
Summary measures and synthesis of results 
We used a random-effects meta-analysis for the primary analyses, allowing for heterogeneity 
between and within studies. Effect estimates derived from studies adjusting for confounders as well 
as those that did not (unadjusted estimates) were pooled in separate meta-analyses. We examined 
heterogeneity with the I2 statistic and identified reasons for heterogeneity using univariable random 
effects meta-regression to compare subgroups by geographical region of study; site of recruitment; 
proportion of female participants; main drug injected; type of NSP; frequency of injecting;  and study 
design. We used sensitivity analyses to determine to what extent the overall intervention effect was 
changed by: the inclusion of studies at severe or unclear risk of bias; the inclusion of studies that did 
not adjust for confounders; exclusion of unpublished datasets; and excluding cross-sectional studies 
that measured intervention effect at baseline only. 
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Results 
The numbers of studies identified, reviewed and selected and the reasons for exclusion for both 
searches are shown in figure 1. We identified 21 published studies that directly included measures of 
the impact of exposure to either OST or NSP on HCV transmission.12, 24-43 In addition we identified 11 
eligible prospective studies that measured HCV incidence and contacted authors of these articles.44-
54 Of these, unpublished data were obtained from cohort studies in Montreal (Canada)55; Baltimore 
(USA)56, San Francisco (USA),57 Sydney and Melbourne (Australia)58, 59,  London (UK)60 and three 
cross-sectional surveys in Bristol, Birmingham, Leeds.61 In total we included 1736 HCV incident 
infections and 6513.04 person years of follow-up. Overall HCV incidence ranged between 5.9 and 42 
cases per 100 person years across the studies.  
 
[Insert Figure 1] 
 
Description of studies 
Table 1 summarises the characteristics of the included studies undertaken in the USA (n=8), UK 
(n=5), Canada (n=5), Australia (n=5) and one study each in the Netherlands, France, Italy, Spain and 
China.  Twenty one of the included studies reported the impact of OST. 12, 24, 25, 30, 31, 34, 36-38, 40-43, 55-
62Seventeen studies reported the impact of NSP. 12, 26-29, 32, 33, 35, 39, 41, 43 55-57, 59, 60 Four studies assessed 
the impact of combined NSP with OST.12, 29, 32, 55 There were no experimental studies. Sample size 
varied from 46 to 2788 with participants recruited through street outreach, respondent driven 
sampling, or service providers. Twenty five studies reported the sex of participants, of which the 
mean proportion of women across the studies was 32% (range 2.8-55.9%). Three were excluded 
from this analysis since they only published unadjusted estimates of lifetime use of OST versus never 
using OST.36, 41, 42 
 
[Insert Table 1] 
Risk of bias 
Risk of bias decisions are summarised in last column of Table 1 and in the Web appendix (Table A). 
Only two studies were judged at moderate overall risk of bias,38, 40 seventeen studies were judged as 
serious overall risk of bias,24, 26-33, 37, 39, 41, 43, 55, 59 and seven were at critical risk.25, 34-36, 42, 58, 60 For two 
studies,56, 57 we did not have enough information to make a judgment.  
 
Current use of opioid substitution therapy 
We pooled data from a total of 17 studies that measured current OST12, 24, 25, 30-32, 34, 37, 38, 40, 41, 43 
including five unpublished estimates.55, 58-61 Twelve studies (6361 participants) presented adjusted 
measures, on which the primary analyses were focused.24, 30, 31, 34, 38, 40, 43, 55, 56, 59, 60, 62 Random effect 
meta-analysis of multivariable estimates showed that OST was associated with a 50% reduction in 
the risk of HCV infection (Risk ratio=0.50) with little heterogeneity between studies (I2=0, p=0.889).  
 
[Insert Figure 2] 
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This effect was maintained when the analysis was limited to exclude two studies judged to be at 
critical risk of bias34, 60 and one study where there was insufficient information to give an overall risk 
of bias assessment56 (Risk ratio=0.51, I2=0%, p=0.68,). The intervention effect was unchanged when 
the analysis excluded two cross-sectional studies34, 62 that reported baseline measures of effect only 
(3367 participants Risk ratio=0.51, I2=0.0%, p=0.73). The intervention effect strengthened when 
estimates from four unpublished data sources55, 56, 59, 60 were excluded (Risk ratio=0.42, I2=0%, 
p=0.96).  The intervention effect weakened slightly and heterogeneity increased if all unadjusted 
estimates were pooled from 16 studies (10647 participants, Risk ratio=0.57, I2=32.4, p=0.09 (Figures 
A-D, web appendix). 
We found no evidence that effectiveness varied by geographical region (Figure 2) or study design. 
We did find evidence of differential impact in the proportion of female participants in the sample. 
With each 10% increase of female participants in sample, the effect of intervention exposure was 
reduced (Ratio of rate ratios=1.59) (Table 2). 
 
High coverage of needle syringe programmes 
Five studies (3530 participants) reported adjusted measures of high NSP coverage compared to no or 
low NSP coverage and HCV incidence 27, 29, 33, 62 including one unpublished dataset.55 Random effect 
meta-analysis showed weak evidence of an effect of high coverage of NSP on the reduction in the 
risk of HCV infection (Risk ratio= 0.79) and high heterogeneity between studies (I2 =77%, p=0.002). 
Random effects meta-analysis of 7 studies (6455 participants) that presented unadjusted estimates 
show that the weak intervention effect was unchanged (Risk ratio= 0.77, I2=79%, p=0.000001) 
(Figure 4). Evidence of any intervention effect became weaker after excluding the unpublished 
dataset55 (Risk ratio=0.77, p<0.001). No NSP studies were rated critical on the risk of bias tool (Figure 
E Web appendix).  
 
[Insert Figures 3 and 4] 
 
High NSP coverage was associated with a 56% reduction in HCV acquisition risk (Risk ratio=0.44) with 
low heterogeneity (I2=12.3%, p=0.337) when pooling unadjusted estimates from Europe but no 
effect for North America and high heterogeneity (RR=1.58, I2=89.5%, p=0<0.001). (Figure 4) This 
pattern was maintained in the pooling of adjusted estimates with a reduction in HCV acquisition 
associated with high NSP coverage in Europe (RR=0.24) and low heterogeneity (I2=0, p=0.66) but not 
in North America.(RR=1.58) and high heterogeneity (I2=89.5, p<0.001) (Figure 3). The meta-
regression analysis also showed evidence of differential impact by region comparing North America 
with Europe (Ratio of rate ratios= 3.73, p=0.06) (Table 3). Univariable meta regression analysis also 
suggested some association between high coverage of NSP and study design (Ratio of rate 
ratios=3.5, p value=0.087 comparing cross-sectional with longitudinal study design), this was 
reduced when adjusted for geographical region (Ratio of rate ratios=1.7, p value=0.577). We found 
no evidence of differential impact by proportion of female participants in the sample, homelessness 
or experience of prison.  
 
[Insert Table 2] 
 
Combination interventions: OST and high/low NSP 
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Random effects meta-analysis pooling adjusted measures from three studies12, 55, 62 (3241 
participants) showed that combined use of OST and high coverage of NSP was associated with a 74% 
risk reduction in HCV acquisition (Risk ratio=0.26, I2=80% p=0.007). This effect was maintained when 
pooling unadjusted measures from 4 studies (3356 participants, Risk ratio= 0.29, I2=64.4% p=0.038) 
(Figure 6). 
 
[Insert Figure 5] 
 
The effect of exposure to OST and low coverage of NSP from pooling adjusted measures from two 
studies (2956 participants) was weaker (Risk ratio=0.87, I2=36.0% p=0.67). This effect remained 
unchanged when pooling unadjusted measures from three studies (3071 participants) (Risk 
ratio=0.76, I2=29.6% p=0.24) (Figure 6). 
 
[Insert Figure 6] 
 
Publication bias 
A funnel plot of 13 estimates (12 studies) and Egger’s bias coefficient (−0.87 p=0.106) suggested no 
evidence of publication bias in studies of current OST exposure. A funnel plot of 5 estimates (5 
studies) and Egger’s bias coefficient (−1.65 p=0.54) suggested little evidence of publication bias in 
studies of high NSP coverage, although this analysis only included 5 studies and may be under 
powered. (Figures F and G in web appendix). 
 
Quality of evidence 
Evidence for current use of OST is considered to be low quality because it was derived from 
observational studies with serious risk of bias. Evidence for combined use of OST and NSP was also 
considered to be low quality. Evidence for the effect of NSP was judged to be very low quality 
(because of the high heterogeneity and smaller effect size) according to the GRADE criteria23. These 
are reported in detail in the Cochrane Review.21 
 
Discussion 
Main Findings 
Opioid substitution treatment (OST) is consistently associated with an average 50% reduction in the 
risk of new HCV infections among PWID. The combined use of high coverage NSP with OST is 
associated with an average reduction in risk of HCV infection by 74%. There is weaker evidence that 
high coverage of NSP is associated with a reduction in risk of new HCV infections globally. There 
were no trials identified in the review. The majority of the observational studies were assessed to be 
at severe or critical risk of bias, and the strength of the evidence generated was low in the case of 
OST and very low for NSP.21   
Strengths and Limitations 
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The two key limitations of the review are heterogeneity in measurement of exposure to NSPs and 
confounding. Consistent measures of NSP exposure through coverage of injections by clean 
needles/syringes were used across the European studies{Hope, 2011 #5}{Hope, 2015 #50}{Van Den 
Berg, 2007 #31}{Palmateer, 2014 #63}, whereas the North American studies drew on varied 
definitions of NSP use that focussed on frequency of attendance at NSPs.{Patrick, 2001 #9}{Hagan, 
1999 #4}{Bruneau, 2015 #48} The measure of 100% NSP coverage corresponds to the situation 
where a person reports that they receive sufficient or a greater number of sterile syringes per 
reported injecting frequency and is found in sites which allow PWID to collect a large number of 
syringes or attend very regularly rather than in sites which adopt a more restricted form of 
exchange. It is possible also that the population exposed to 100% coverage are more compliant than 
the comparison group in terms of regular attendance and uptake of needles/syringes.  However, we 
cannot assume that they necessarily use all needles/syringes obtained since HCV transmission still 
occurs in this population. Inconsistencies in NSP measurement contributed to heterogeneity 
observed among studies (I2=77%, p=0.002), while differences in study design, exposure 
measurement, and patterns of injecting may have contributed to the lack of effect of NSPs on HCV 
transmission observed in North America. The European definition of coverage may include 
needles/syringes obtained from pharmacies, secondary distribution via friends or via outreach 
whereas the North American definition is specific to fixed site NSP use. In reality PWID may obtain 
needles/syringes from multiple sources and, as a consequence, use NSPs less frequently for social 
support, HIV/HCV testing and counselling and other specialist advice. These additional services are 
essential to prevent the spread of blood-borne viruses and reduce inequalities in health over time63, 
but the immediate effect on HCV incidence may be difficult to assess where measurement  of 
exposure doesn’t capture uptake of sterile needles/syringes from other sources. Measurement of 
NSP use that focuses on needles/syringes without taking into account acquisition of other drug 
preparation equipment from NSPs may also have contributed to the lack of an association in some 
settings, particularly in the US where nearly half of HCV seroconversions have been attributed to the 
shared use of cookers (spoons) and cottons.5 It is also hypothesised that less frequent use of NSPs 
and lack of federal funding for NSPs in the United States has resulted in lower coverage among PWID 
overall which may mask an intervention effect, although in cities where the studies took place 
coverage is not as low as for the US overall.64 65 The higher proportion of stimulant injectors in US 
studies also may contribute to lower impact. Meta regression analysis suggested no differential 
impact between intervention effect and study design for current use of OST, but did suggest that 
longitudinal studies of NSP found a lower effect than cross-sectional studies which were associated 
with European settings.  
The control of confounders was limited and inconsistent across the studies. However, synthesised 
effect estimates for OST and combined effect of OST and high coverage NSP were consistent across 
multiple studies and maintained between analyses that adjusted for confounders and those that did 
not, suggesting the variation did not affect the results. We cannot rule out the effect of residual 
confounding on NSP – especially for the lack of association between NSP use and HCV from studies 
in North America. For example, it has been shown that people who attend NSPs regularly in North 
America also report greater injecting risk behaviours and other social vulnerabilities (including sex 
work or homelessness) and that after adjustment for these factors any positive association between 
HCV or HIV transmission and NSP attendance is reduced.66 67 
An additional limitation is that the GRADE criteria used by Cochrane automatically assesses evidence 
from observational studies as low quality.23 The merits and limitations of using Cochrane Reviews 
and GRADE criteria in developing guidelines in the addictions field has been recently discussed68 
alongside a recognition for the need to separate out the quality of the evidence from the strength of 
the ensuing recommendation.69 We agree this is an important distinction to make when examining 
the effect of interventions where there is no experimental evidence and it is not ethical to conduct 
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randomised controlled trials. Observational studies can give misleading results and in some notable 
examples have been shown to be false when compared to evidence from randomised trials.70 
Nonetheless, consideration of other criteria for assessing quality of evidence may be needed – such 
as size of effect, consistency across sensitivity analyses, supporting evidence, and use of 
instrumental variables to test for confounding.23  
Other Evidence 
This is the first global quantitative systematic review of the effectiveness of OST and NSP on 
reducing HCV – building on an earlier narrative review that OST and NSP reduce injecting risk and 
global reviews on HIV.  14, 17{Aspinall, 2014 #38} Our findings corroborate a pooled analysis, which 
suggested that receiving OST and high coverage of NSP can reduce HCV infection risk alone, but is 
greater in combination.20 Our findings suggested a stronger effect of high NSP coverage in Europe, 
but no effect in North America. This corroborates findings from another review that found increased 
risk of seroconversion associated with NSP attendance that relied on evidence predominantly from 
North America.19 Meta-regression analysis suggested evidence of a differential impact of OST by the 
proportion of female participants in the sample with the effectiveness of the intervention reduced 
by 59% with every 10% increase in female participants. This corroborates other evidence that 
women are at increased risk of acquiring hepatitis C compared to men and may have poorer access 
to OST, possibly as a result of services not taking into account gender-specific needs or being tailored 
towards men.{Iversen, 2015 #69}{Miller, 2004 #70}{Tracy, 2014 #72} 
Implications 
Given the low quality of evidence for NSP, there is an urgent need to improve transparency and 
consistency in reporting of observational studies in order to support future natural experiments and 
systematic reviews measuring the impact of the intensity of intervention coverage on HCV and other 
outcomes. The development of improved and consistent measures of NSP coverage along with more 
consistent reporting of the conduct of studies to measure exposure to NSPs and the assessment of 
confounders are needed to strengthen the evidence on the impact of NSP. 
It has been noted that the greatest benefits for people with mental health and addiction problems 
including PWID will be derived from providing better evidenced-based care in relation to medication, 
substitution therapies and abstinence programmes, as well as addressing underlying social problems 
arising from homelessness and criminalisation.{Sederer, 2014 #108} This is particularly relevant in 
low and middle-income countries where resources may be more restricted.68 There is a wealth of 
evidence from high-income settings of the beneficial effects of OST in reducing injecting injection 
related harms, including HIV and bacterial infections, and improving access to services.11, 17, 19, 20, 71, 72 
However, global coverage of OST remains very low, prohibited in the Russian Federation and often 
restricted by age or duration of dependency prior to treatment entry.73 Our findings show the need 
to remove restrictions on the concurrent use of both NSP and OST to maximise reduction in HCV 
transmission. We had insufficient data to measure the impact of OST dosage on HCV acquisition risk, 
but two studies that stratified by dose showed that reduced risk was associated with high doses of 
methadone (≥60mg) pointing to the importance of providing adequate dosages.{Van Den Berg, 2007 
#31;Bruneau, 2015 #48} Distribution of needles/syringes through NSPs needs to be maintained 
alongside provision of OST. NSP and OST services also need to develop gender-sensitive policies and 
practices to encourage women to use services addressing gender-specific injecting related risk and 
other health and social welfare needs. The potential role of the new era of highly curative short-
course direct-acting antiviral therapies for HCV to reduce HCV transmission also needs to be 
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considered,{Martin, 2011 #109} and within this the importance of ensuring equitable access of PWID 
to OST and NSPs that can facilitate HCV testing and treatment. In summary, our findings provide 
strong evidence that OST and in combination with high coverage NSP should be expanded to prevent 
the transmission of HCV and reduce associated morbidity and mortality.  
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Table 1: Characteristics and risk of bias of included studies  
Author Design Sex Age  N HCV/ 
100 
py 
New HC/py Interventions   Effect estimate  Confounders included in analysis Rick 
of 
bias 
Aitken, 
201558 
Australia 
Cohort 31.7
% 
29.4 
(median) 
98 8.6 17/196 OST current 
Use of OST in last month  
HR 0.8(0.3-2.0) 
 
- C 
Bruneau, 
201555 
Canada 
Cohort NA 37.4% 
<30  
285 17.3 102/589.35 OST current 
Use of OST in last 6 months 3 
HR 0.74 (0.47-1.16 ) 
AOR=0.74 (0.47-
1.16) 
Years injecting, numbers of injection in past 
month 
S 
       NSP (high; 
High NSP (>100% coverage) 
HR 0.77 (0.5-1.19) 
AOR=0.7 (0.45-
1.09) 
Years injecting, numbers of injection in past 
month 
 
       Combined NSP/OST OST in last 
6 months & high (>100% 
coverage)  
HR 0.63 (0.37-1.07) 
AOR=0.59 (0.35-
1.01) 
Years injecting, numbers of injection in past 
month 
 
       OST other^  (high dose ≥60 mg) HR 0.37 (0.17-0.8) 
AOR=0.39 (0.18-
0.86) 
Years injecting, numbers of injection in past 
month 
 
       OST other^ (low dose <60 mg) HR 1.15 (0.7-1.89) 
AOR=1.06 (0.64-
1.77) 
Years injecting, numbers of injection in past 
month 
 
Craine, 
200924 Wales 
Cohort 29.0
% 
27.2 
(mean) 
286 5.9 17/287.33 OST current  
In OST at interview   
IRR 0.27 (0.095-0.77) 
AOR=0.34 (0.12-
0.99) 
Region, homelessness, sharing equipment, 
sharing needles (all in last 12 months) 
 
Crofts, 199725 
Australia 
Cohort* 41.9
% 
29.2 
(mean) 
73 22.2 13/85.4 OST current  
Continuous OST during follow 
up  
IRR 1.8 (0.37-4.77) - S 
       OST other^ (Interrupted use) IRR 0.66 (0.55-0.79) -  
Hagan, 
199526 USA 
Case-
control  
45.0
% 
24% < 25  46  20/NA NSP (low)^ 
Ever used NSP  
OR 0.12 (0.026-0.55) 
AOR=0.14 (0.03-
0.62) 
Sex, age, ethnicity, and duration of injection S 
Hagan, 
199927 USA 
Cohort 38.0
% 
19% <25  187 20.8 26/209 NSP (high) 
current regular NSP use  
RR 1.42 (0.64-3.13) 
AOR=1.31 (0.79-
Onset of injection < 1 year from baseline 
interview, sharing at baseline 
S 
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Author Design Sex Age  N HCV/ 
100 
py 
New HC/py Interventions   Effect estimate  Confounders included in analysis Rick 
of 
bias 
2.2) 
       NSP (low)^ 
 
 1.72 (0.71-4.19) 
AOR=2.59 (0.79-
8.5) 
Onset of injection < 1 year from baseline 
interview, sharing at baseline 
 
Holtzman, 
200928 USA 
Cohort 38.0
% 
28%  <21  128
8 
 139/NA NSP (low) ^ 
NSP use in the last 6 months  
OR 1.22 (0.86-1.74) 
AOR=1.49 (0.96-
2.29) 
Duration of injection, shared needles/ 
paraphernalia; daily injecting; injecting with 
others 
S 
Hope, 201129 
UK 
Cross-
sectiona
l 
23.0
% 
17%  <25  119 40 14/35 NSP alone (high);  
high NSP (≥100% coverage 
IRR 0.11 (0.024-0.53) - S 
       NSP/OST combined 
OST in last 6 months & high 
(>100% coverage)  
IRR 0.17 (0.12-1.54) -  
       NSP/OST combined 
OST in last 6 months & low 
(<100% coverage)  
IRR 1.08 (0.31-3.82) -  
Hope, 201561 
UK 
Cross-
sectiona
l 
25.0
% 
 919 9.9 30.3 OST current 
Use of OST in last 4 weeks 
Birmingham: 
Bristol: 
Leeds 
OR  
 
1.55 (0.14-17.4) 
0.24 (0.05-1.16) 
1.31 (0.08-21.5) 
- S 
       NSP high NSP coverage (≥100% 
coverage) (Low NSP, no OST) 
Bristol: 
Leeds: 
Birmingham: 
OR  
 
0.99 (0.21-4.59) 
0.73 (0.04-11.98) 
0.55 (0.05-6.26) 
-  
Judd, 201560 
UK 
Cohort 29.0
% 
27.4  149 42 49/116.7 OST current 
Use of methadone in last 6 
months  
RR 0.47 (0.16-1.33) 
AOR=0.49 (0.17-
1.47) 
Duration  and frequency of  injecting C 
Lucidarme, 
200430 France 
Cohort 17.6
% 
26.9 
(mean) 
165 11 16/178.4 OST current 
No definition  
RR 0.34 (0.11-0.99) 
AOR=0.41 (0.12-
1.4) 
Sex, geographical region, condom use, daily 
injection of cocaine, duration of injecting, 
sharing paraphernalia (cotton, cup, water) 
S 
15 
 
Author Design Sex Age  N HCV/ 
100 
py 
New HC/py Interventions   Effect estimate  Confounders included in analysis Rick 
of 
bias 
Maher, 
201559 
Australia 
Cohort 38.0
% 
24 
(median) 
368 24.9 53/212.86 OST current 
OST in last 6 months  
HR 0.43 (0.24-0.75) 
AOR=0.46 (0.25-
0.84) 
Duration  and frequency of  injecting S 
       NSP (low)^ HR 1.86 (1.05-3.28) 
AOR=0.15 (0.88-
2.78) 
Duration  and frequency of  injecting  
Mehta, 
201556 USA 
Cohort  34 
(median) 
324 17.8 27/166.5 OST current  
OST in last 6 months  
IRR 0.6 (0.14-2.51) 
AOR=0.82 (0.19-
3.54) 
Years injecting, daily injection, age (for 
whole cohort) 
N/I 
       NSP (low)^ IRR 1.38 (0.17-11.5) 
aor=0.76 (0.1-5.67) 
Years injecting, daily injection, age (for 
whole cohort) 
 
Nolan, 201431 
Canada 
Cohort 30.4
% 
23-34 100
4 
6.32 184/2108.4 OST current 
MMT in last 6 months  
OR 0.67 (0.45-0.99) 
AOR=0.47 (0.29-
0.76) 
Uunstable housing, cocaine, heroin or 
methamphetamine injection, cohort and 
year of recruitment, follow-up time 
S 
Page, 201557 
USA 
Cohort 21.7
% 
33.7 
(mean) 
552 25.1 171/681.3 NSP (low) ^ 
NSP use in the last 3 months   
HR 2.82 (1.84-4.34) 
AOR=2.62 (1.71-
4.02) 
Years injecting, age, sex, race, homeless, 
and recent jail 
N/I 
Palmateer, 
201432 
Cross-
sectiona
l 
27.5
% 
34 
(mean) 
278
8 
7.3 392/602.7 OST current; OST at time of 
survey; low NSP (<200%)  
OR 0.51 (0.29-0.9) 
AOR=0.52 (0.23-
1.18) 
Survey year, homelessness  or stimulant 
injection in last 6 months, time since onset 
of injecting 
S 
Scotland       NSP (high) 
high  NSP (>200%) coverage and 
not on OST; 
OR 0.26 (0.08-0.88) 
AOR=0.18 (0.04-
0.87) 
Survey year, homelessness in last 6 months, 
stimulant injection in last 6 months, time 
since onset of injecting 
 
       OST/NSP combined;  
high  NSP (>200%) coverage  
OR 0.24 (0.1-0.6) 
AOR=0.05 (0.01-
0.18) 
Survey year, homelessness in last 6 months, 
stimulant injection in last 6 months, time 
since onset of injecting 
 
       OST/NSP combined;  
low  NSP (<200%) coverage  
OR 0.48(0.27-0.95) 
AOR=0.59 (0.26-
1.35) 
Survey year, homelessness in last 6 months, 
stimulant injection in last 6 months, time 
since onset of injecting 
 
Patrick, 
200133 
Canada 
Cohort 30.3
% 
34 
(median) 
155 29.1 62/207.95 NSP (high) 
Attendance at least 1 per week 
at NSP in last 6 months  
HR 3.69 (2.12-6.43) 
AOR=2.56 (1.37-
6.79) 
Sex, injection of cocaine or speedballs, 
frequency of injection  
S 
16 
 
Author Design Sex Age  N HCV/ 
100 
py 
New HC/py Interventions   Effect estimate  Confounders included in analysis Rick 
of 
bias 
Rezza, 199634 
Italy 
Case-
control  
2.8% 21% >28  106 28.6 21/73.4 OST current 
OST in last 6 months 
OR AOR=0.34 (0.10-
1.11) 
Female gender, age, duration of drug use, 
injection of cocaine 
C 
Ruan, 200736 
China 
Cohort  44% <28  86 33.0 47/258 OST other^ 
Ever used OST  
RR 0.5 (0.2-1.3) - C 
Roy, 200735 
Canada 
Cross-
sectiona
l  
27.0
% 
31.8 
(mean) 
359 27.1 94/267 NSP (low) ^ 
Use of NSP in last 6 months  
HR 3.02 (95% CI n/a) Age, injection experience, injection with 
used needle, drug most often injected, sex 
work, district of recruitment 
C 
Spittal, 
201237 
Canada 
Cohort 53.4
% 
23 
(median) 
148 11.6 45/338.6 OST current  
In OST at time of survey 
(yes/no) 
HR 2.11 (0.83-5.37) - S 
Thiede, 
200038 
Cohort 48.9
% 
5.4% < 25  80 8.75 7/80 OST current  
Continuous use during follow- 
up  
OR 0.3 (0.01-3.6) 
AOR=0.4 (0.0-4.2) 
Injected at follow-up, pooled money to buy 
drugs, injected with used needles, 
backloading 
M 
USA       OST other^ 
Interrupted left treatment at 
least 1 during follow up 
OR 0.8 (0.01-3.6) 
AOR=1.2 (0.2-7.3) 
Injected at follow-up, pooled money to buy 
drugs, injected with used needles, 
backloading 
 
Thorpe, 
200239 USA 
Cohort 39.7
% 
52% 18-
22 years 
353 10 29/327.2 NSP (low) ^ 
Use of NSP in last 6 months  
HR 1.29 (0.6-2.79 Receptively sharing syringes, sharing 
cookers, cotton filters,  rinse water or  
backloading 
S 
Tsui, 201440  
USA 
Cohort 31.9
% 
16% 15-
18  
552 25.1 145/680 OST current & other 
Opiate agonist therapy 
maintenance treatment in last 3 
months;  
HR 0.31 (0.14-0.65) 
AOR=0.39 (0.18-
0.87) 
Age, duration of injection drug use, sex, 
ethnicity, homelessness or incarceration in 
past 3 months 
M 
       OST other ^Opiate agonist 
detoxification in last 3 months  
HR 1.45 (0.8-2.69) Age, duration of injection drug use, sex, 
ethnicity, homelessness  or incarceration in 
past 3 months 
 
Vallejo, 
201541 Spain 
Cohort 27.3
% 
40% ≥25  137 39.8 42/105.4 OST other^ 
Lifetime use of OST  
IRR 0.9 (0.5-1.6) - S 
Van Den 
Berg, 200712   
Cohort 33.0
% 
31.4 
(median) 
168 6.78 57/598.56 OST current;  
OST ≥60 mg methadone daily 
IRR 0.67 (0.39-1.13) - S 
Netherlands       NSP alone; High NSP (100% 
coverage)  
IRR 0.62 (0.3-1.3) -  
17 
 
Author Design Sex Age  N HCV/ 
100 
py 
New HC/py Interventions   Effect estimate  Confounders included in analysis Rick 
of 
bias 
       Combined OST/NSP high NSP  RR 0.15 (0.05-6-0.4) 
AOR=0.36 (0.13-
1.03) 
Duration of injection, HIV status of steady 
partner 
 
       Combined OST/NSP low NSP  RR 1.04 (0.53-2.05) 
AOR=1.17 (0.59-
2.31) 
Duration of injection, HIV status of steady 
partner 
 
       OST other^ (high dose) RR 0.68 (0.39-1.13)   
       OST other^ (Low dose) RR 0.58 (0.3-1.15)   
Van Beek, 
199842 
Australia 
Cohort* 55.9
% 
61.5% 
<20  
152 20.9 26/148.2 OST other^ 
Ever used OST (yes/no) 
OR 1.08 (0.37-3.17)  C 
White, 201443 
Australia 
Cohort 25.0
% 
27 
(median) 
127 7.9 20/215.2 OST: OST last 6 months  
 
HR Heroin users 0.65 
(0.15-2.94) 
AOR=0.56 (0.12-
2.56) 
Amphetamine 
users 0.14 (0.04-
0.51) 
AOR=0.51(0.18-
0.04) 
Sex, ethnic background, age, daily or more 
frequent injecting, receptive syringe sharing 
and not receiving OST while reporting 
heroin or other opioids as the main drug 
injected 
S 
White, 201443 
Australia 
      NSP (low) ^ Accessed NSP in last 
6 months; 
HR 1.0 (0.36-2.86) -  
HR=Hazard Ratio OR=Odds Ratio RR=Risk Ratio IRR=incident rate ratio  ^Not reported in the primary analysis N/A=Not available Risk of bias: C=Critical; 
S=Serious; M=Moderate; L=Low; N/I=No information. HCV incidence for cross-sectional surveys calculated as I=[(365/T)n]/[(N-n)+(365/T)n] where 
I=Incidence, T= estimated mean duration of the HCV antibody-negative/RNA positive ‘window period’ = 75 days, n= number of HCV incident infections (HCV 
antibody negative and HCV RNA positive) and N=number of susceptibles (HCV antibody negative) 
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Table 2: Univariable metagression analysis for studies measuring impact of current use of OST and high coverage NSP on HCV incidence 
 Current use of OST  High coverage of NSP   
Variable 
Studie
s 
Univariable rate 
ratio (95% CI) 
Ratio of rate 
ratios 95%CI 
P 
value 
Tau 
squared 
I2 Studie
s 
Univariable rate 
ratio (95% CI) 
Ratio of rate 
ratios (95%CI) 
P 
value 
Tau 
squared 
I2 
Geographic Region              
Europe 8 0.51 (0.37-0.70) 1.0 (ref)    5 0.44 (0.24-0.80) 1.0 (Ref)    
Australia 5 0.55 (0.28-1.11) 1.12 (0.52-2.41)          
North America 6 0.69 (0.44-1.08) 1.42 (0.73-2.78) 0.53 0.1032 33.7% 3 1.58 (0.57-4.42) 3.73 (0.95-14.7) 0.057 0.41 71.7% 
Site of 
Recruitment 
            
Service attenders 12 0.67 (0.49-0.92) 1.0 (ref)    3 0.67 (0.28-1.59) 1.0 (Ref)    
Community 7 0.49 (0.33-0.73) 0.73 (0.42-1.27) 0.256 0.06 32.3% 5 0.82 (0.29-2.32) 0.76(0.12-4.88) 0.74 0.89 79.9% 
Study design             
Cross sectional 4 0.51 (0.31-0.85) 1.0    3 0.34 (0.16-0.75) 1.0 (Ref)    
Prospective cohort 15 0.58 (0.43-0.77) 1.12 (0.48-2.61) 0.784 0.1001 35.3% 4 1.26 (0.55-2.93) 3.53 (0.78-15.86) 0.087 0.478 74.5% 
Females 17  1.59 (1.13-2.29) 0.01 0.04 13.8% 7  2.97(0.38-23.1) 0.24 0.87 81.3% 
Prison 11  
1.057 (0.61-
1.79) 
0.821 0.4303 
56.3% 
3  n/a   
 
Homelessness 12  1.08 (0.83-1.40) 0.521 0.2327 39.8% 6  1.01 (0.38-2.67) 0.976 1.53 80.6% 
Injection of 
stimulants 
12  0.89 (0.65-1.22) 0.373 0.17 
36.2% 
7  1.08 (0.47-2.51) 0.827 1.15 
80.4% 
19 
 
Daily injection 7  0.88 (0.64-1.22) 0.373 0.17 47.3% 5  3.66 (0.22-61.3) 0.239 1.15  
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Figure 1: Flow chart of included studies  
6814 records identified through database 
searching with IMPACT search 
 
(MEDLINE: 932; PsycINFO: 451; Global Health: 
575; EMBASE: 2298; CINAHL: 123; WOS: 1679; 
CENTRAL: 630; DARE: 13; NHSEED: 20; HTA: 3; 
CLIB: 21; CDAG register:69) 
6720 records after duplicated removed 
Records screened 
(n =6720) 
Records excluded 
(n =6576) 
Full-text articles assessed 
for eligibility 
(n =144) 
Full-text articles excluded, 
with reasons 
(n = 103 referring to 101 
studies) 
Studies awaiting 
classification (n=10) 
Studies included in 
qualitative synthesis 
(n = 28, (31 articles)) 
Studies included in 
quantitative synthesis 
(meta analysis) (n= 28) 
6996 records identified through database 
searching with LONGITUDINAL search 
 
(MEDLINE: 1926; PsycINFO: 284; Global 
Health: 248; EMBASE: 2276; CINAHL: 74; 
WOS: 1808) 
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Figure 2: Impact of current use of OST versus no OST on HCV incidence from studies adjusted for 
confounders and stratified by region 
 
 
 
Figure 3: Impact of high coverage NSP versus no/low coverage on HCV incidence from studies 
adjusted for confounders and by region 
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Figure 4 Impact of high coverage NSP versus no/low coverage on HCV incidence from pooling 
unadjusted measures by region 
 
 
Figure 5: Impact of OST combined with high coverage NSP from studies adjusting for confounders 
and all pooled estimates 
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Figure 6: Impact of OST combined with low coverage NSP from studies adjusting for confounders and 
all pooled estimates 
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